TY - JOUR
T1 - Prognostic Value of the G2 Expression Signature and MYC Overexpression in Childhood High-Grade Osteosarcoma
AU - Van Ewijk, Roelof
AU - Hiemcke-Jiwa, Laura S.
AU - Hehir-Kwa, Jayne Y.
AU - Gaspar, Nathalie
AU - Haveman, Lianne M.
AU - Flucke, Uta E.
AU - Dandis, Rana
AU - Van Tuil, Marc
AU - Janda, Claudia Y.
AU - Van De Sande, Michiel A.J.
AU - Van Der Heijden, Lizz
AU - Koudijs, Marco J.
AU - Merks, Johannes H.M.
AU - Tops, Bastiaan B.J.
AU - Marchais, Antonin
AU - Kester, Lennart A.
N1 - Publisher Copyright:
© 2025 American Society of Clinical Oncology.
PY - 2025/5/1
Y1 - 2025/5/1
N2 - PURPOSEIn high-grade osteosarcoma, prognostic factors at diagnosis are insufficient for stratifying patients into relevant subgroups. Recently, a transcriptomic study developed the G1/G2 gene expression signature, in which the G2 signature was associated with unfavorable survival. An orthogonal study identified MYC amplification as an unfavorable prognostic factor using targeted next-generation sequencing. The purpose of this study was to validate the independent prognostic value and to investigate the combined prognostic value of the G1/G2 signature with MYC amplification and/or MYC expression for survival prediction.MATERIALS AND METHODSThis study included pediatric and adolescent patients with high-grade osteosarcoma. RNA-seq was performed in 48 patients. Whole-exome sequencing was performed in 40 patients. Gene expression signature scores, MYC amplification (defined as >seven copies), and MYC expression levels were calculated. Multivariable Cox proportional hazards analysis was performed for event-free survival (EFS; primary end point) and overall survival (OS; secondary end point).RESULTSIn the full cohort, the 3-year EFS rate was 37%. In multivariable Cox regression analysis with metastatic disease stage (n = 21, 44%) as covariate, the G2 signature and MYC expression were independently associated with worse outcomes in terms of EFS (hazard ratio [HR], 3.32 [95% CI, 1.34 to 8.21] and HR, 3.38 [95% CI, 1.71 to 6.66], respectively) and OS (HR, 4.07 [95% CI, 1.19 to 13.9] and HR, 2.88 [95% CI, 1.22 to 6.76], respectively). MYC amplification was not associated with EFS or OS in univariable analysis (HR, 1.88 [95% CI, 0.74 to 4.77] and HR, 0.79 [95% CI, 0.21 to 3.05], respectively).CONCLUSIONThe G2 gene expression signature and MYC expression were independently associated with unfavorable outcomes in a pediatric cohort of patients with high-grade osteosarcoma. The combined prognostic value warrants further prospective validation and could potentially serve as a stratification marker for future osteosarcoma treatment protocols.
AB - PURPOSEIn high-grade osteosarcoma, prognostic factors at diagnosis are insufficient for stratifying patients into relevant subgroups. Recently, a transcriptomic study developed the G1/G2 gene expression signature, in which the G2 signature was associated with unfavorable survival. An orthogonal study identified MYC amplification as an unfavorable prognostic factor using targeted next-generation sequencing. The purpose of this study was to validate the independent prognostic value and to investigate the combined prognostic value of the G1/G2 signature with MYC amplification and/or MYC expression for survival prediction.MATERIALS AND METHODSThis study included pediatric and adolescent patients with high-grade osteosarcoma. RNA-seq was performed in 48 patients. Whole-exome sequencing was performed in 40 patients. Gene expression signature scores, MYC amplification (defined as >seven copies), and MYC expression levels were calculated. Multivariable Cox proportional hazards analysis was performed for event-free survival (EFS; primary end point) and overall survival (OS; secondary end point).RESULTSIn the full cohort, the 3-year EFS rate was 37%. In multivariable Cox regression analysis with metastatic disease stage (n = 21, 44%) as covariate, the G2 signature and MYC expression were independently associated with worse outcomes in terms of EFS (hazard ratio [HR], 3.32 [95% CI, 1.34 to 8.21] and HR, 3.38 [95% CI, 1.71 to 6.66], respectively) and OS (HR, 4.07 [95% CI, 1.19 to 13.9] and HR, 2.88 [95% CI, 1.22 to 6.76], respectively). MYC amplification was not associated with EFS or OS in univariable analysis (HR, 1.88 [95% CI, 0.74 to 4.77] and HR, 0.79 [95% CI, 0.21 to 3.05], respectively).CONCLUSIONThe G2 gene expression signature and MYC expression were independently associated with unfavorable outcomes in a pediatric cohort of patients with high-grade osteosarcoma. The combined prognostic value warrants further prospective validation and could potentially serve as a stratification marker for future osteosarcoma treatment protocols.
UR - http://www.scopus.com/inward/record.url?scp=105007144252&partnerID=8YFLogxK
U2 - 10.1200/PO-24-00855
DO - 10.1200/PO-24-00855
M3 - Article
AN - SCOPUS:105007144252
VL - 9
JO - JCO Precision Oncology
JF - JCO Precision Oncology
M1 - e2400855
ER -